Clinical Trials

MainTitle

The Effectiveness of SMS in Improving Antiretroviral Medication Adherence Among Adolescents Living With HIV in Nigeria (STARTA)

This study has been completed
Sponsor
Dr. Olumide ABIODUN


Information provided by (Responsible Party)
Dr. Olumide ABIODUN, Babcock University

ClinicalTrials.gov Identifier
NCT03394391

First received: December 28, 2017
Last updated: November 13, 2019
Last Verified: November 2019
History of Changes
Purpose

Purpose

The non-maintenance of ART adherence is a major barrier to the achievement of optimal treatment outcomes among adolescents living with HIV. ART adherence is a challenge among adolescents living with HIV because of lack of appropriate information, their unique emotional state and lifestyles but the most commonly quoted challenge to adherence is forgetting to take antiretroviral drugs. There is evidence to suggest that short message service (SMS) reminder- interventions may enhance drug compliance among adolescents living with other chronic diseases such as asthma and diabetes. Available literature underscores the need for randomized controlled trials (RCTs) of effective interventions to promote ART adherence among adolescents with HIV.

The aim of this study is to evaluate the feasibility, acceptability, and efficacy of interactive and tailored SMS reminders on ART adherence among adolescents (15-19 years) living with HIV in Ogun State, Nigeria. The study hypothesizes that the use of personal mobile phones and SMS reminders for the improvement of ART adherence among adolescents living with HIV are feasible, acceptable, and effective.

A single-blind, parallel-design (ratio 1:1), and multi-center RCT of 230 adolescent living with HIV who are non-adherent to medications will be conducted over a one-year period in Southwest Nigeria. All the participants will receive routine adherence counseling during clinic visits and one SMS reminder each for follow-up appointments 48 hours and 24 hours before the follow-up visit date. The intervention group will also receive daily ART adherence reminder SMS. Participants will be assessed at baseline and during follow-up visits at 4, 8, 12, 16 and 20 weeks after the baseline. Baseline assessment of participants will include socio-demographic characteristics; HIV/AIDS risk behaviour assessment, Alcohol and Drug abuse assessment, Client Satisfaction Survey, ART adherence assessment, CD4count and viral load assessments. ART adherence and client satisfaction will be assessed at each follow-up visit while CD4count and viral load assessments will be done at baseline and at 20th week.

It is possible that tailored SMS reminders will mitigate the barrier of forgetfulness in ART-adherence and lead to improved drug compliance, viral suppression, and quality of life among adolescents living with HIV.

Condition Intervention
HIV Infections

Behavioral : Daily ART-adherence SMS reminder
Behavioral : Standard Adherence Counselling/Patient experience group chat

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A single-blind, parallel-design (ratio 1:1), and multi-centre RCT of 230 adolescent living with HIV who are non-adherent to medications will be conducted over a one-year period in Southwest Nigeria.
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Single-blind, Randomized, Parallel Design Study to Assess the Effectiveness of SMS Reminders in Improving ART Adherence Among Adolescents Living With HIV in Nigeria (STARTA Trial-Adolescents)

Further study details as provided by Dr. Olumide ABIODUN, Babcock University:

Primary Outcome Measures

  • ART Adherence at 20 Weeks as Determined by VAS, Viral Load [ Time Frame: 20week [End of study] ]
    ART adherence is assessed by different well-validated methods. In this study, ART adherence will be measured, primarily, using the self-report visual analog scale. The scale is well-validated, self-report of the level of ART adherence with a range from 0 to 100%. While higher values indicate better levels of adherence, patients with adherence levels of 95% and above are regarded as ART-adherent while those with values less than 95% are not adherent to ART medications. Viral load is the number of copies of viral RNA detected in participants' blood. Participants with viral load
  • ART Adherence at 20 Weeks as Determined by Pill Counts, ACTG Adherence Questionnaire, and VAS Scores [ Time Frame: 20week [End of study] ]
    AIDS Clinical Trials Group Scale scores range from 0 to 1. The higher scores reflect better ART adherence Pill count scores also range from 0 to 1 and the higher scores also reflect better adherence. Visual analog scale [VAS] adherence ranges between 0 and 100%. Higher scores reflect better ART adherence
  • ART Adherence at 20 Weeks as Determined by Viral Load Count [ Time Frame: 20 week [End of study] ]
    Viral load count is measured in copies per ml. The minimum value is 0. There is no maximum value. The higher values reflect poor adherence
  • ART Adherence at 20 Weeks as Determined by Log of Viral Load Count [ Time Frame: 20week [End of study] ]
    log of viral load count is log 10 transformation of the viral load values
Secondary Outcome Measures:
  • Patient Satisfaction Score at 20 Weeks [ Time Frame: End of Study (20weeks) ]
    Patient satisfaction will be assessed using a 22-item adaptation of the SERVQUAL tool. It is a multi-dimensional service quality assessment tool that uses a 5-point likert scale scored from 1 to 5 points to assess 5 domains of client satisfaction. The domains are tangibility (4 items; scores from 4 to 20), reliability (5 items; scores from 5 to 25), responsiveness (4 items; scores from 4 to 20), assurance (4 items; scores from 4 to 20), and empathy (5 items; scores from 5 to 25). Patient satisfaction is measured by the total score which will range between 22 and 110. Higher scores indicate better client satisfaction.
  • Number of Participants With Mental Distress Determined by General Health Questionnaire 12 at 20 Weeks [ Time Frame: End of study (20weeks) ]
    The General Health Questionnaire 12 (GHQ12) will be used to assess the mental health status of all the participants. It is a well-validated and widely used instrument for screening for mental health distress. It is a 12-item questionnaire that is based on a 4-point likert scale scored from 0 to 3 points. The scores will range between 0 and 36. A score of 12 or more is suggestive of mental distress while scores less than 12 suggest that mental distress is absent.

Enrollment: 212
Study Start Date: July 5, 2018
Study Completion Date: June 30, 2019
Primary Completion Date: May 3, 2019 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Intervention group
Daily ART-adherence SMS reminder
Behavioral: Daily ART-adherence SMS reminder

Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.

Behavioral: Standard Adherence Counselling/Patient experience group chat
  • All the participants will receive the standard adherence counselling by trained counsellors at each visit.
  • All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges.

Active Comparator: Control group
Standard adherence counselling/Patient experience group chat
Behavioral: Standard Adherence Counselling/Patient experience group chat
  • All the participants will receive the standard adherence counselling by trained counsellors at each visit.
  • All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges.

Detailed Description:

BACKGROUND In Nigeria, approximately 3.2 million people were living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) in Nigeria. Nigeria has about 196,000 adolescents (10-19 years) living with HIV with an estimated 17,000 new infections and 11,000 AIDS-related deaths per year in the age group. Adolescents aged 15 to 19 years constitute 8.8% of Nigeria's over 173 million people and have an HIV prevalence rate of 2.9%.
Non-adherence to antiretroviral therapy (ART) increases the risk of non-suppression of HIV, secondary HIV transmission, and development of drug resistance; it has a negative impact on treatment outcomes, leads to decreased survival and worsened quality of life. Adolescents on ART have lower viral suppression rates (49%) when compared with both adults and younger children (72.8% and 57%) and this is one of the most frequent causes of lower adherence to ART.
The non-maintained ART adherence is a major barrier to the achievement of optimal treatment outcomes among adolescents living with HIV. ART adherence is a challenge among adolescents living with HIV because of lack of appropriate information, their unique emotional state and lifestyles. Religious, cultural, social and health services related factors have also been recognized as a source of non-adherence to ART treatment. Other known barriers to ART adherence include difficult dosing schedule, side effects, food restrictions and pill burden but the most commonly quoted challenge to adherence is forgetting to take antiretroviral drugs. Many strategies, including directly observed drug use, adherence counselling, telephone calls and reminder devices adopted to enhance ART adherence have turned out to be time-consuming, costly and intrusive.
With over 148 million active mobile lines, short message service (SMS) has become a common means of communication in Nigeria. SMS is used commonly by teenagers, including those who are economically disadvantaged. SMS has been applied in a variety of healthcare setting because of its low-cost and convenient technology and has proved to be an effective tool for behavioural change interventions. There is evidence to suggest that SMS interventions may enhance drug compliance among adolescents living with other chronic diseases such as asthma and diabetes. An RCT showed that text-messaging system increased adherence to medication among adolescents by about 7%. While studies have evaluated the effectiveness of SMS reminders on ART adherence among PLHIV in some low-resource settings, to the best of our knowledge studies that evaluated SMS reminders for adolescents living with HIV have not yet been published. Indeed, a Cochrane systematic review of randomized controlled trials (RCTs) that assessed the effectiveness of SMS for improving ART adherence among people living with HIV infection identified the need of RCTs for this intervention among adolescents.
Mobile technology communicates interventions to people in real-time and in their natural habitat. A review of the literature on SMS interventions for behavioural change in health care settings identified key characteristics for success such as interactivity and tailored messages.
PROJECT OBJECTIVES Objective 1: To evaluate the efficacy of interactive and tailored SMS reminders on ART adherence among adolescents (15-19 years) living with HIV in Southwest, Nigeria.
Objective 2: To assess the feasibility and acceptability of using personal mobile phones and interactive and tailored SMS reminders for the improvement of ART adherence among adolescents living with HIV in Southwest, Nigeria.
Objective 3: To identify the predictors of ART non-adherence among adolescents (15-19 years) living with HIV in Southwest, Nigeria.
STUDY HYPOTHESES

  1. Interactive and tailored SMS reminders are efficacious in the improvement of ART adherence among adolescents (15-19) years living with HIV.
  2. The use of personal mobile phones for the improvement of ART adherence among adolescents living with HIV is feasible and acceptable.
  3. ART adherence among adolescents is predicted by demographic, socioeconomic, and psychosocial factors.

METHODOLOGY Study design and procedure This study is designed to have 80% power to detect a difference of 20%. When the proportion of adolescents who are adherent to ART was taken as 49% (5), a sample size of 104 per group was obtained. The study will recruit 230 participants from the ART clinics in Southwest Nigeria into a randomized controlled trial (RCT). Convenience sampling method by which participants will be recruited on routine clinic visits across five (5) high patient-density ART sites will be used.
For the purpose of this study, we defined poor adherence as self-reported < 95% adherence in the preceding one month using a validated visual analogue scale. Self-reported 95% adherence level is an ideal cut-off point because self-reported measures tend to exaggerate adherence and such high adherence level will minimize the occurrence of false-negatives.
Initial eligibility screening and recruitment will be carried out by the primary caregivers using a checklist. Potential participants who meet the first four criteria will be presented with a visual analogue scale (VAS) labelled 0 to 100% at intervals of 5%. Eligible and willing participants will then be referred to the research assistants for a comprehensive informed consent process.
Baseline activities
At the baseline, the research assistants will give the volunteer participants a detailed explanation of the study, including its aim, duration, intervention and possible benefits. All the volunteers will be required to give a signed informed consent in a private room. Adolescents aged 15 to 19 years are thought to be relatively mature. According to a brief of AIDS regulations and Laws in Nigeria, children who are deemed mature in this context are capable of giving informed consent. Besides, based on evidence from South Africa and Lesotho, the WHO recommended that the legal age of consent for HIV testing and treatment should be 12 years. The consenting volunteers will then be allocated unique identifiers that they will maintain throughout the course of the study. The contact details of the lead investigator will be made available to the participants so that he can be reached directly for any reason that is related to the study. Baseline data will be obtained in a private room by trained research assistants using structured interviewer-administered paper-based questionnaires over a period of about 40 minutes. The questionnaire will assess:
  • socio-demographic variables.
  • HIV/AIDS risk behaviour assessment: This will be done using the AIDS Risk Behavior Assessment (ARBA); a validated, adolescent-specific tool for the assessment of sexual behaviour, drug and alcohol use, and HIV-associated needle use. It assesses sexual behaviour over the previous 30 days and the previous three months.
  • Alcohol and Drug abuse assessment: The Alcohol Use Disorders Identification Test (AUDIT) will be used to assess alcohol abuse. AUDIT, which was developed in 1982 by the World Health Organization, is a simple tool that is used to screen for and to identify people who are at risk of alcohol problems. The drug abuse screening test (DAST-20, adolescent version) will be used to screen for drug abuse. DAST is a validated scale that was designed to provide a brief, self-reported instrument for population screening, clinical case finding, and treatment evaluation research. It yields a quantitative index of the drug abuse consequences.
  • Client Satisfaction Survey: A 22-item adaptation of the SERVQUAL tool will be used for this purpose. First published in 1988, the SERVQUAL is a multi-dimensional tool that assesses patients expected and perceived quality of services across five domains. Its use currently dominates research and industry for the assessment of quality of services and is well-validated in HIV service quality assessment.
  • Adherence assessment: This will be done using the validated visual analogue scale (described above), monthly pill count, pharmacy records and the AIDS Clinical Trials Group (ACTG) adherence questionnaire. The research assistants will carry out pill counts and obtain the pharmacy records. Adherence assessment will be carried out at baseline and at every follow-up visit.

  • Ten millilitres (10 ml) of blood samples will also be taken by laboratory scientists to measure the volunteers' CD4 cell count and HIV viral load. Sampling collection, handling and disposal will follow the standards and guidelines outlined by the WHO and PEPFAR. The participants' capability to operate mobile phones will be enhanced. The research assistants will work with participants to select from a list the most preferred SMS that will serve as a daily reminder of ART adherence. Each participant will select an SMS format that will serve as a reminder for follow-up visit reminders. In addition, the participants will also choose the preferred language and time for SMS reminders. The messages will be designed in such a way that they are sensitive and protect the privacy of the participants. The participants will be able to contact the lead investigator if they wish to change their chosen messages or if the services to their mobile phones are disrupted.
    Data Analysis The research assistants will code and enter the data obtained into Microsoft excel software in the CSV format. The data will be exported to the STATA version 15/SE for analyses. The data manager will fully review 5% (one in every twenty) questionnaire for errors. The data manager in conjunction with the investigators will be responsible for baseline, interim and final data analysis. The investigators, data manager, research assistants, counsellors and other project staff will be blinded throughout the study. After the scientific review has been completed and data collection has been completed, at the point of analysis, a list of participants' unique identifiers in two groups will be sent to the data analysts without specifying which the investigation or control group is. The blinding of the clinical database will finally be removed after final data analysis has been completed.
    Statistical Methods Intention-to-treat analysis will be carried out. Baseline characteristics will be compared using the chi-square test, rank-sum test, and independent t-test as appropriate. The independent t-test will be used to compare the means of ART adherence between the investigation and control groups after each follow-up visit in order to test if the intervention has any effect. The incidence proportion, incidence rate, relative risk, risk difference, and odds ratio will be used to measure the effect. Survival analysis will also be carried out to adjust for censoring (competing risk and loss to follow-up). Multiple regression analyses will be used to control for possible confounders. Subgroup analysis will also be undertaken in order to generate further hypotheses.
    The acceptability of the SMS will be accessed by the responses given by participants. The proportion of participants who find the method acceptable will be determined.
    The feasibility will be determined using the proportion of participants who are deemed to have completed the study (participate fully).
    The study will also assess client satisfaction and the possible effect of adherence on the mental health status of adolescents. Correlation and linear regression analyses will be used to determine the association between adherence (percent) and mental health status (GHQ 12 measure).

    Eligibility

    Eligibility

    Ages Eligible for Study: 15 Years to 19 Years  
    Sexes Eligible for Study: All  
    Accepts Healthy Volunteers: No  

    Criteria

    Inclusion Criteria:

    • HIV seropositivity
    • Being on ART for at least three month
    • Age 15 to 19 years as at last birthday
    • Use of personal mobile phone
    • Poor adherence to ART

    Exclusion Criteria:

      Adolescents who are too ill to require hospital admission will be excluded from the study.

    contacts and locations

    Contacts and Locations

    Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

    Please refer to this study by its ClinicalTrials.gov identifier: NCT03394391

    Locations

    Nigeria
    Lagos State University Teaching Hospital
    Ikeja, Lagos, Nigeria
    The Nigerian Institute of Medical Research
    Yaba, Lagos, Nigeria
    Federal Medical Center
    Abeokuta, Ogun State, Nigeria
    State Hospital
    Ijebu-Ode, Ogun State, Nigeria
    State Hospital
    Ota, Ogun State, Nigeria

    Sponsors and Collaborators

    Dr. Olumide ABIODUN

    Investigators

    Principal Investigator: Olumide ABIODUN, FWACP Babcock University
    More Information

    More Information

    Additional Information:

    AIDSInfo for Nigeria

    Additional Information:

    Nigeria's Phone subscribers increase to 152.1 million

    Additional Information:

    AIDS Law Brief; Age of Consent for HIV Testing and Counseling in Nigeria

    Additional Information:

    Drug Abuse Screening Test (DAST-20)

    Additional Information:

    Drug Abuse Screening Test (DAST) - Adolescent Version

    Additional Information:

    ACTG Adherence Baseline and Follow up Questionnaires

    Additional Information:

    Patient Satisfaction Survey for HIV Ambulatory Care

    Additional Information:

    National HIV Strategy for Adolescents and Young People 2016-2020

    Additional Information:

    ADOLESCENT HIV TESTING, COUNSELLING AND CARE Implementation guidance for health providers and planners

    Additional Information:

    Teens and Mobile Phones

    Additional Information:

    The Alcohol Use Disorders Identification Test: Interview version

    Additional Information:

    Laboratory guidelines for enumerating CD4 T lymphocytes in the context of HIV/AIDS

    Additional Information:

    Standard Operating Procedures on Viral Load Monitoring for ICAP Clinical Staff and Health Care Workers: A Template Document for Country Adaptation

    Additional Information:

    General principles of good chronic care

    Additional Information:

    Is a simple self-rating or visual analogue scale more accurate than prescription refill data, as an indicator of non-adherence in a resource-limited setting in South Africa?

    Responsible Party: Dr. Olumide ABIODUN, Senior Lecturer and Honorary Consultant, Babcock University  
    ClinicalTrials.gov Identifier: NCT03394391   History of Changes  
    Other Study ID Numbers: BUTH/CT/0001  
      MISP Database number #57473  
    Study First Received: December 28, 2017  
    Last Updated: November 13, 2019  
    Individual Participant Data    
    Plan to Share IPD: Yes  

    Studies a U.S. FDA-regulated Drug Product: No  
    Studies a U.S. FDA-regulated Device Product: No  

    Keywords provided by Dr. Olumide ABIODUN, Babcock University:

    Adherence
    Adolescents
    Antiretroviral therapy
    HIV
    Nigeria
    Randomized controlled trial
    Short message services

    Additional relevant MeSH terms:
    HIV Infections

    ClinicalTrials.gov processed this data on June 02, 2020
    This information is provided by ClinicalTrials.gov.